These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37740935)

  • 1. Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.
    Mok S; Roycroft E; Flanagan PR; Wagener J; Fitzgibbon MM
    J Antimicrob Chemother; 2023 Nov; 78(11):2637-2644. PubMed ID: 37740935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
    Kadura S; King N; Nakhoul M; Zhu H; Theron G; Köser CU; Farhat M
    J Antimicrob Chemother; 2020 Aug; 75(8):2031-2043. PubMed ID: 32361756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant
    Trisakul K; Nonghanphithak D; Chaiyachat P; Kaewprasert O; Sakmongkoljit K; Reechaipichitkul W; Chaiprasert A; Blair D; Clark TG; Faksri K
    Emerg Microbes Infect; 2022 Dec; 11(1):1857-1866. PubMed ID: 35792049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
    He W; Liu C; Liu D; Ma A; Song Y; He P; Bao J; Li Y; Zhao B; Fan J; Cheng Q; Zhao Y
    J Glob Antimicrob Resist; 2021 Sep; 26():241-248. PubMed ID: 34214699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.
    Nimmo C; Millard J; van Dorp L; Brien K; Moodley S; Wolf A; Grant AD; Padayatchi N; Pym AS; Balloux F; O'Donnell M
    Lancet Microbe; 2020 Aug; 1(4):e165-e174. PubMed ID: 32803174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
    Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
    Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
    Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K
    J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
    Zheng H; He W; Jiao W; Xia H; Sun L; Wang S; Xiao J; Ou X; Zhao Y; Shen A
    BMC Infect Dis; 2021 Apr; 21(1):330. PubMed ID: 33832459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The
    Mansjö M; Karlsson Lindsjö O; Grönfors Seeth C; Groenheit R; Werngren J
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0102622. PubMed ID: 36409105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants and their association with phenotypic resistance to bedaquiline in
    Ismail N; Rivière E; Limberis J; Huo S; Metcalfe JZ; Warren RM; Van Rie A
    Lancet Microbe; 2021 Nov; 2(11):e604-e616. PubMed ID: 34796339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.
    Battaglia S; Spitaleri A; Cabibbe AM; Meehan CJ; Utpatel C; Ismail N; Tahseen S; Skrahina A; Alikhanova N; Mostofa Kamal SM; Barbova A; Niemann S; Groenheit R; Dean AS; Zignol M; Rigouts L; Cirillo DM
    J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32907992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
    Zimenkov DV; Nosova EY; Kulagina EV; Antonova OV; Arslanbaeva LR; Isakova AI; Krylova LY; Peretokina IV; Makarova MV; Safonova SG; Borisov SE; Gryadunov DA
    J Antimicrob Chemother; 2017 Jul; 72(7):1901-1906. PubMed ID: 28387862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
    Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective
    Kaniga K; Hasan R; Jou R; Vasiliauskienė E; Chuchottaworn C; Ismail N; Metchock B; Miliauskas S; Viet Nhung N; Rodrigues C; Shin S; Simsek H; Smithtikarn S; Ngoc ALT; Boonyasopun J; Kazi M; Kim S; Kamolwat P; Musteikiene G; Sacopon CA; Tahseen S; Vasiliauskaitė L; Wu MH; Vally Omar S
    J Clin Microbiol; 2022 Jan; 60(1):e0291920. PubMed ID: 34705538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
    Gómez-González PJ; Perdigao J; Gomes P; Puyen ZM; Santos-Lazaro D; Napier G; Hibberd ML; Viveiros M; Portugal I; Campino S; Phelan JE; Clark TG
    Sci Rep; 2021 Sep; 11(1):19431. PubMed ID: 34593898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
    Ismail NA; Omar SV; Moultrie H; Bhyat Z; Conradie F; Enwerem M; Ferreira H; Hughes J; Joseph L; Kock Y; Letsaolo V; Maartens G; Meintjes G; Ngcamu D; Okozi N; Padanilam X; Reuter A; Romero R; Schaaf S; Te Riele J; Variava E; van der Meulen M; Ismail F; Ndjeka N
    Lancet Infect Dis; 2022 Apr; 22(4):496-506. PubMed ID: 34780706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of Canonical and Noncanonical Genomic Variants following
    Ismail N; Dippenaar A; Warren RM; Peters RPH; Omar SV
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0136822. PubMed ID: 36892309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.